Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
Benjamin Solomon, MBBS, PhD, FRACP
Advertisement
Articles by Benjamin Solomon, MBBS, PhD, FRACP
Benjamin Solomon, MBBS, PhD, FRACP, discusses interim findings from the phase 3 CROWN study in ALK-positive non–small cell lung cancer.
Advertisement
Latest Updated Articles
Dr. Solomon on the Results of the Phase 3 CROWN Study in ALK-Positive NSCLCPublished: September 20th 2020 | Updated:
ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLCPublished: November 17th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL
5